Adverse event totals12

The totals the trial posted for each group.

1 to 12 of 12

Total	Group	Affected	At risk
Total, all-cause mortality	Placebo
Total, all-cause mortality	Mavrilimumab 30 mg
Total, all-cause mortality	Mavrilimumab 100 mg
Total, all-cause mortality	Mavrilimumab 150 mg
Total, other adverse events	Placebo	38	81
Total, other adverse events	Mavrilimumab 30 mg	41	81
Total, other adverse events	Mavrilimumab 100 mg	36	85
Total, other adverse events	Mavrilimumab 150 mg	43	79
Total, serious adverse events	Placebo	1	81
Total, serious adverse events	Mavrilimumab 30 mg	4	81
Total, serious adverse events	Mavrilimumab 100 mg	5	85
Total, serious adverse events	Mavrilimumab 150 mg	2	79

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01706926/event-totals